MBC Advocate, following MBC breakthroughs
NYC
Joined October 2022
- Tweets5.1K
- Following1K
- Followers1.4K
- Likes15.7K
Puma ALISCA - Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. $PBYI #SABCS26 #JPM27 businesswire.com/news/home/2…
NEW MBC Clinical Trial MEKanistic Therapeutics: First-in-Human Phase 1, Open-label Study to Evaluate the Safety, Clinical Activity, Pharmacokinetics & Pharmacodynamics of MTX-531 a Dual EGFR/PI3K Inhibitor as Monotherapy in Adults w/ Advanced Solid Tumors Metastatic Breast Cancer
Monitoring PD-L1 changes in circulating tumor-associated immune cells following initiation of immunotherapy may provide information regarding clinical benefit in pts w/MBC & are consistent w/findings reported in Bria-IMT Phase 2 study $BCTX $BCTXL #ESMO26 morningstar.com/news/globe-n…
Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01. #ESMO26 #BCAM prnewswire.com/news-releases…
“Efficacy, safety, and biomarker analysis of DB-1310 (HER3-targeted ADC) in pretreated HR+/HER2- metastatic breast cancer: Updated global phase 1/2a trial” #ESMO26 #BCAM scri.com/news/sarah-cannon-r…
The US Oncology Network, will present “Real world (RW) outcomes in HR+/HER2- metastatic breast cancer (MBC) patients, by second-line (2L) treatment” #ESMO26 #BCAM scri.com/news/sarah-cannon-r…
The US Oncology Network will present “First-in-class Rac/Cdc42 inhibitor MBQ-167 in patients with metastatic breast cancer (MBC): safety and preliminary efficacy” #ESMO26 #BC scri.com/news/sarah-cannon-r…
Findings from analysis of metastatic breast cancer patients support further evaluation of circulating CAML PD-L1 as a potential biomarker of clinical benefit from immunotherapies, including BriaCell’s earlier Phase 1/2 Bria-IMT study. $BCTX $BCTXL #ESMO26 biospace.com/press-releases/…
Dynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAML) were significantly associated w/ progression-free survival and overall survival following immunotherapies including the BriaCell regimen. $BCTX $BCTXL #ESMO26 investingnews.com/briacell-a…
Overall survival favored abemaciclib plus fulvestrant after disease progression on prior CDK4/6i & endocrine therapy. Numerically longer mOS 32 m. vs 25 m. Updated PFS, PFS2 & chemo-free survival all favored abemaciclib plus fulvestrant. $AZN $LLY #ESMO26 mededgemea.com/new-cancer-tr…
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. $AZN $LLY #ESMO26 #BCAM annalsofoncology.org/article…
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Metastatic Breast Cancer at the ESMO Congress 2026. #ESMO26 $CELC #BCAM globenewswire.com/news-relea…
Great News! “Preclinical data demonstrate tumor response with AVA6103 in the setting of Enhertu resistance.
Potential for prolonged responses with increased FAP+ fibroblasts recruited to the tumor during treatment with AVA6103.” #AVCT #ESMO26 morningstar.com/news/globe-n…
💔🕊️ GONE TOO SOON. NEVER FORGOTTEN. SUZANNE SOMERS.
Three years ago, we lost Suzanne Somers from metastatic breast cancer, just one day before her 77th birthday. An iconic television star who brought laughter into millions of homes. Her cancer returned as metastatic. #BCAM
Avacta will present the most recent data analysis from the Phase 1a trial of Faridoxorubicin (AVA6000) & the design of the FOCUS-01 trial of FAP-Exd (AVA6103) in two poster presentations at the European Society for Medical Oncology #ESMO26 Congress. #AVCT kalkinemedia.com/uk/news/ann…
🚨METASTATIC BREAST CANCER ACTION MONTH: DAY 3. BREAST CANCER DOESN’T END WITH THE FIRST DIAGNOSIS. About 30% of pts diagnosed w/early-stage breast cancer eventually develop metastatic disease. About 10% are diagnosed De Novo Stage IV metastatic breast cancer from the start #BCAM
